title: Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function.
abstract: OBJECTIVE
  Surgical excision remains the standard and most reliable curative treatment for eyelid carcinoma, but frequently causes functional and cosmetic impairment of the eyelid. We therefore investigated the efficacy and safety of radiation therapy in eyelid carcinoma.
  
  
  METHODS
  Twenty-three patients with primary carcinoma of the eyelid underwent radiation therapy. Sebaceous carcinoma was histologically confirmed in 16 patients, squamous cell carcinoma in 6, and basal cell carcinoma in 1. A total dose of 50-66.6 Gy (median, 60 Gy) was delivered to tumor sites in 18-37 fractions (median, 30 fractions).
  
  
  RESULTS
  All but 3 of the 23 patients had survived at a median follow-up period of 49 months. The overall survival and local progression-free rates were 87% and 93% at 2 years, and 80% and 93% at 5 years, respectively. Although radiation-induced cataracts developed in 3 patients, visual acuity in the other patients was relatively well preserved. There were no other therapy-related toxicities of grade 3 or greater.
  
  
  CONCLUSIONS
  Radiation therapy is safe and effective for patients with primary carcinoma of the eyelid. It appears to contribute to prolonged survival as a result of good tumor control, and it also facilitates functional and cosmetic preservation of the eyelid.
authors.affiliation: Department of Radiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan. mhata@syd.odn.ne.jp
authors.forename: M
authors.initials: M
authors.lastname: Hata
authors.forename: I
authors.initials: I
authors.lastname: Koike
authors.forename: J
authors.initials: J
authors.lastname: Maegawa
authors.forename: A
authors.initials: A
authors.lastname: Kaneko
authors.forename: K
authors.initials: K
authors.lastname: Odagiri
authors.forename: T
authors.initials: T
authors.lastname: Kasuya
authors.forename: Y
authors.initials: Y
authors.lastname: Minagawa
authors.forename: H
authors.initials: H
authors.lastname: Kaizu
authors.forename: Y
authors.initials: Y
authors.lastname: Mukai
authors.forename: T
authors.initials: T
authors.lastname: Inoue
mesh_terms: D018266:Adenocarcinoma, Sebaceous / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D001767:Blinking / Q000528:radiation effects; D002280:Basal Cell Carcinoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D002423:Cause of Death; D004954:Esthetics; D005142:Eyelid Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005143:Eyelids / Q000528:radiation effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D066298:In Vitro Techniques; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011835:Radiation Protection / Q000295:instrumentation; D018714:Radiotherapy, Adjuvant / Q000295:instrumentation; D015996:Survival Rate; D014785:Vision, Ocular / Q000528:radiation effects*